MOLNbenzinga

Molecular Partners Presents New Preclinical Data On Radio-DARPin And Switch-DARPin Programs At AACR 2025; First Preclinical Data Of Novel Targeted Radio-DARPin Against Mesothelin, In Co-Development With Orano Med

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 25, 2025 by benzinga